5-(4-aminophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine | 605661-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 5-(4-aminophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
• CAS: 605661-13-0
• 化学式: C₁₃H₁₂N₄S
• 分子量: 256.331
• InChiKey: XEYSOBWTYDZKAV-UHFFFAOYSA-N

物化性质

• 沸点：
  494.6±45.0 °C(Predicted)
• 密度：
  1.381±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-aminophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 N-[4-(4-amino-6-methylthieno[2,3-d]pyrimidin-5-yl)phenyl]-N'-methyl-N'-(3'-methylphenyl)urea
  参考文献：
  名称：

  Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors

  摘要：

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).

  DOI：

  10.1021/jm050458h
• 作为产物：
  描述：

  6-methyl-5-(4-nitrophenyl)thieno[2,3-d]pyrimidin-4-amine 在 铁粉 、 氯化铵 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 1.0h， 生成 5-(4-aminophenyl)-6-methylthieno[2,3-d]pyrimidin-4-amine
  参考文献：
  名称：

  Thiopyrimidine and isothiazolopyrimidine kinase inhibitors

  摘要：

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。

  公开号：

  US20030225273A1

文献信息

• Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors
  申请人：Michaelides R. Michael

  公开号：US20060276490A1

  公开（公告）日：2006-12-07

  Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有公式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还揭示了制备该化合物的方法，含有该化合物的组合物以及使用该化合物的治疗方法。
• THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS
  申请人：AbbVie Inc.

  公开号：EP1487841B1

  公开（公告）日：2014-01-15
• US7560552B2
  申请人：——

  公开号：US7560552B2

  公开（公告）日：2009-07-14
• Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
  申请人：——

  公开号：US20040014756A1

  公开（公告）日：2004-01-22

  Compounds having the formula 1 are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• Thienopyrimidine Ureas as Novel and Potent Multitargeted Receptor Tyrosine Kinase Inhibitors
  作者：Yujia Dai、Yan Guo、Robin R. Frey、Zhiqin Ji、Michael L. Curtin、Asma A. Ahmed、Daniel H. Albert、Lee Arnold、Shannon S. Arries、Teresa Barlozzari、Joy L. Bauch、Jennifer J. Bouska、Peter F. Bousquet、George A. Cunha、Keith B. Glaser、Jun Guo、Junling Li、Patrick A. Marcotte、Kennan C. Marsh、Maria D. Moskey、Lori J. Pease、Kent D. Stewart、Vincent S. Stoll、Paul Tapang、Neil Wishart、Steven K. Davidsen、Michael R. Michaelides

  DOI：10.1021/jm050458h

  日期：2005.9.1

  A series of novel thienopyrimidine-based receptor tyrosine kinase inhibitors has been discovered. Investigation of structure-activity relationships at the 5- and 6-positions of the thienopyrimidine nucleus led to a series of N,N '-diaryl ureas that potently inhibit all of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor tyrosine kinases. A kinase insert domain-containing receptor (KDR) homology model suggests that these compounds bind to the "inactive conformation" of the enzyme with the urea portion extending into the back hydrophobic pocket adjacent to the adenosine 5 '-triphosphate (ATP) binding site. A number of compounds have been identified as displaying excellent in vivo potency. In particular, compounds 28 and 76 possess favorable pharmacokinetic (PK) profiles and demonstrate potent antitumor efficacy against the HT1080 human fibrosarcoma xenograft tumor growth model (tumor growth inhibition (TGI) = 75% at 25 mg/kg-day, per os (po)).